Literature DB >> 7034810

In situ immunologic characterization of cellular constituents in lymph nodes and spleens involved by Hodgkin's disease.

S Poppema, A K Bhan, E L Reinherz, M R Posner, S F Schlossman.   

Abstract

The cellular constituents in lymph nodes and spleens of patients with Hodgkin's disease were studied with a series of monoclonal antibodies directed against human thymocyte, peripheral T-cell, and la antigens. Utilizing both an immunoperoxidase technique on frozen tissue sections and indirect immunofluorescence on cell suspensions, wer found that a majority of lymphocytes were T cells, since they stained with anti-T1 and anti-T3 antibodies, which react with all peripheral T cells. In addition, most of these cells were reactive with anti-T4 antibody, which defines the helper/inducer T-cell population, whereas only a minority of cells stained with anti-T5 and anti-T8 antibodies, which are reactive with suppressor/cytotoxic T cells. Moreover, a large proportion of T cells expressed T10 antigen, which is found on activated T cells. A minority of the T cells also expressed la antigen(s), again suggesting that some of the T cells are activated. In contrast, the Reed-sternberg cells did not react with any of these anti-T-cell antibodies or with anti-IgM antiserum, but displayed strong membrane and cytoplasmic staining with anti-la antibody. Taken together, these findings suggest that Reed-Sternberg cells are not of T-cell lineage but may be derived from antigen-presenting reticulum cells in the thymus-dependent areas of lymphoid tissues; these cells are normally associated with T4+ cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7034810

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

Review 1.  Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Authors:  Polina Shindiapina; Lapo Alinari
Journal:  Ther Adv Hematol       Date:  2018-03-05

2.  Absence of HLA class I expression by Reed-Sternberg cells.

Authors:  S Poppema; L Visser
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

3.  Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease. Evidence for a dendritic or B cell derivation?

Authors:  G S Pinkus; J L Pinkus; E Langhoff; F Matsumura; S Yamashiro; G Mosialos; J W Said
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

4.  Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.

Authors:  Johanna Veldman; Lydia Visser; Magdalena Huberts-Kregel; Natasja Muller; Bouke Hepkema; Anke van den Berg; Arjan Diepstra
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

5.  Nodular sclerosing, mixed cellularity and lymphocyte-depleted variants of Hodgkin's disease are probable dendritic cell malignancies.

Authors:  I C Kennedy; D N Hart; B M Colls; J C Nimmo; D A Willis; H B Angus
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

6.  The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease.

Authors:  S Poppema
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

7.  Monoclonal antibodies (MT1, MT2, MB1, MB2, MB3) reactive with leukocyte subsets in paraffin-embedded tissue sections.

Authors:  S Poppema; H Hollema; L Visser; H Vos
Journal:  Am J Pathol       Date:  1987-06       Impact factor: 4.307

8.  Phenotypic expression of Hodgkin's and Reed-Sternberg cells in Hodgkin's disease.

Authors:  S M Hsu; K Yang; E S Jaffe
Journal:  Am J Pathol       Date:  1985-02       Impact factor: 4.307

9.  Lymphomatoid papulosis and Hodgkin's disease: are they related?

Authors:  R Willemze; E Scheffer; W A Van Vloten; C J Meijer
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

Review 10.  The role of T cells in the microenvironment of Hodgkin lymphoma.

Authors:  Frederik Wein; Ralf Küppers
Journal:  J Leukoc Biol       Date:  2015-08-28       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.